Dzuveo® sublingual sufentanil 30 mcg tablet
Dzuveo® is indicated for the management of acute moderate to severe pain in adult patients.
Click below for the relevant prescribing information for your country:
N° 1 Farleigh House Old Weston Road Flax Bourton, Bristol BS48 1UR United Kingdom | AGUK-277/04-09/2024
Adverse events should be reported. Reporting forms and information can be found at:
UK - www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
IE - HPRA Pharmacovigilance; website: www.hpra.ie
Adverse events should also be reported to Aguettant Ltd. UK: 01275 463691, Ireland: 0143 11350.
Pain control designed for your environment
Whether you work in emergency, trauma, peri-operative or a general medical environment, your ability to control your patient's pain is integral to your role.
The analgesia must support you to quickly achieve patient mobilisation, control over procedures, and avoid complications.
Complications that could lead to delays, worse outcomes and longer hospital stays and affect your team's efficiency, department morale and hospital goals.
Dzuveo® sublingual sufentanil provides efficient (1), fast-acting (2) analgesia that's easy-to-administer, helping you maintain control over your patients’ healthcare experience.
Dzuveo® supports you with pain control designed for your environment.
Your efficient (1), quick (2) and easy way to administer pain relief
Dzuveo® sublingual sufentanil 30 mcg tablet is an option for you to urgently regain pain control.
Fast: Dzuveo® reduces pain intensity within 15-30 minutes (2), maintaining effective analgesia for up to 3 hours (4).
Simple: Dzuveo® comes ready to administer in a single dose tablet of 30mcg of sublingual sufentanil.
Efficient: Dzuveo®'s high lipophilicity means it penetrates the blood brain barrier rapidly, efficiently producing the desired analgesic effect (3).
Safety Information
Dzuveo® is to be administered by a healthcare professional in a medically monitored setting only. A medically monitored setting must have equipment and personnel trained to detect and manage hypoventilation, and availability of supplemental oxygen and opioid antagonists, such as naloxone. Dzuveo® should only be prescribed and administered by healthcare professionals who are experienced in the management of opioid therapy; particularly opioid adverse reactions, such as respiratory depression
3 steps to Dzuveo®
sublingual sufentanil tablets
02
Sign up for our emails to receive the latest news about Dzuveo®, including updates on new clinical data, support tools and product availability.
A pain control option for your toolkit
Other forms of opioid pain relief can have inefficient administration routes, which can have a negative effect on the patient experience and clinical outcomes.
Intravenous (IV) pain relief has associated risks of tissue infiltration or air bubbles (5).
Oral pain medications can have a slow onset of action, are subject to first pass metabolism and are not suitable for many patients.
In contrast, Dzuveo® is available as a ready to use sublingual tablet, which is straightforward and uncomplicated to administer.
Analgesia, designed for your healthcare environment
Post operative
pain
Patients who mobilise sooner recover quicker (6). Dzuveo® supports you to gain control over patient comfort, so they can follow what's needed for their recovery.
Emergency &
trauma pain
In an emergency, relieving pain is an urgent priority. Dzuveo® takes effect quickly to make your patients comfortable, so you can work on their other clinical needs.
Procedural
pain
If a patient experiences pain during their procedure, whether it be a dressing change, burn debridement or an endoscopy, it could affect their overall outcome and clinical experience. Dzuveo®'s efficient analgesia supports you in getting patient pain under control.
Find out more...
To find out more about how our Dzuveo® sublingual sufentanil 30 mcg tablet can support you in providing excellent patient care, request an appointment now.
Simply fill in the form, and an Aguettant team member will arrange a date and time to suit you.
References 1. Electronic Medicines Compendium. (2022) Dzuveo 30mcg Sublingual tablet. Surrey, Electronic Medicines Compendium. 2. Deeks ED. Sufentanil 30 µg Sublingual Tablet: A Review in Acute Pain. Clin Drug Investig. 2019 Apr;39(4):411-418. doi: 10.1007/s40261-019-00772-x. PMID: 30887417. 3. Fisher DM, et al. Anesthesiology. 2018;128(5):943-952 Minkowitz HS, et al. Pain Pract. 2017;17(7):848-858. 4. Miner JR, et al. Pain Management. 2019;9(3):259-271; Fisher DM, et al. Anesthesiology. 2018;128(5):943-952; Minkowitz HS, et al. Pain Pract. 2017;17(7):848-858. DSUVIA [package insert]. Redwood City, CA: AcelRx Pharmaceuticals, Inc; 2019 5. IVWatch. (2022) IV Infiltrations and Extravasations: Causes, Signs, Side Effects, and Treatment. VA, IVWatch. https://www.ivwatch.com/2020/05/27/iv-infiltrations-and-extravasations-causes-signs-side-effects-and-treatment/ 6. Twomey R, Matthews TW, Nakoneshny S, Schrag C, Chandarana SP, Matthews J, McKenzie D, Hart RD, Li N, Sauro KM, Dort JC. Impact of Early Mobilization on Recovery after Major Head and Neck Surgery with Free Flap Reconstruction. Cancers (Basel). 2021 Jun 8;13(12):2852. doi: 10.3390/cancers13122852. PMID: 34201003; PMCID: PMC8227616.
Join our mailing list
Navigate
Social Media
AGUK-277/04-09/2024
Copyright © 2023. All rights reserved.